Last updated: February 21, 2026
What is NDC 51407-0678?
NDC 51407-0678 is the National Drug Code for Tislelizumab, developed by BeiGene. It is an immune checkpoint inhibitor targeting PD-1, approved for multiple cancers including Hodgkin’s lymphoma and non-small cell lung cancer (NSCLC). Its regulatory approval status varies by region, with significant markets including the U.S., China, and the European Union.
Market Overview
Therapeutic Area and Indications
Tislelizumab is classified as an immune checkpoint inhibitor, competing in the oncology space dominated by drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo). Its approved indications, along with pipeline developments, influence market size and growth potential.
| Indication |
Approval Status |
Region |
Market Launch Year |
| Classical Hodgkin’s lymphoma |
Approved |
China, U.S. (pending) |
2019 (China), ongoing in US |
| Non-small cell lung cancer (NSCLC) |
Pending |
China, U.S. |
2022 (China) |
| Other solid tumors |
Clinical trials |
Global |
2023-2025 (expected) |
Market Size and Growth Drivers
The global oncology immunotherapy market was valued at approximately $34.5 billion in 2022, with compound annual growth rate (CAGR) forecast at 10.2% from 2023 to 2030 (Fortune Business Insights). PD-1/PD-L1 inhibitors account for 65% of this [1].
Tislelizumab's primary market—China—had an estimated 10,000+ new cases of Hodgkin’s lymphoma annually, with increasing adoption due to recent approvals. The U.S. market is more mature, with potential to expand through regulatory approvals and additional indications.
Competition and Market Share
Key competitors include:
- Pembrolizumab (Keytruda): Global sales of $14.4 billion in 2022.
- Nivolumab (Opdivo): $7.4 billion globally.
- Toripalimab and camrelizumab: Competing Chinese PD-1 inhibitors with regional market shares.
Tislelizumab aims to capture market share through distinct features such as lower binding affinity to FcγR, which may reduce adverse effects.
Price Projections and Revenue Potential
Current Pricing Landscape
Drug pricing varies significantly by market:
| Market |
Estimated Price per 200 mg Dose |
Notes |
| China |
$1,500 |
Negotiated with minimal rebates |
| U.S. |
$10,000 |
List price for monoclonal antibodies; actual paid varies |
| European Union |
$8,000–$12,000 |
Pricing determined by national authorities |
Cost-to-Patient and Reimbursement
In China, government negotiating bodies often cap prices below list prices, leading to lower revenues. In the U.S., commercial payers and Medicare set reimbursement levels, influencing net sales.
Revenue Projections (2024–2030)
Assuming peak adoption:
- China: Growing from 3,000 to 12,000 annual patient treatments, averaging ~$1,500 per dose.
- U.S. and EU markets: Targeting 10,000–20,000 treated patients annually, with average net prices of approximately $8,000–$10,000 per treatment course.
Estimate:
| Year |
Global Revenue (in millions USD) |
Assumptions |
| 2024 |
$250 |
Initial uptake, limited approvals |
| 2025 |
$500 |
Increased indications, wider approval |
| 2027 |
$1,200 |
Peak market penetration, expanded pipeline |
| 2030 |
$2,000 |
Continued market expansion, increased treatment volume |
Sensitivity Factors
- FDA and EMA approvals for additional indications.
- Market penetration rate in China, U.S., and Europe.
- Pricing adjustments due to negotiations and competitive pressure.
- Emergence of biosimilars or new competitors.
Risks and Opportunities
Risks
- Regulatory delays in key markets.
- Competitive pressure from established PD-1 inhibitors.
- Pricing pressure in mature markets.
- Potential safety concerns affecting adoption.
Opportunities
- Expanding indications including combination therapies.
- Entering new geographic markets.
- Developing biosimilars or enhanced formulations.
Key Takeaways
- NDC 51407-0678 is Tislelizumab, with current focus on oncology indications primarily in China and the U.S.
- Market size is driven by increasing cancer incidence and immunotherapy adoption.
- Price per treatment course ranges from $1,500 in China to $10,000+ in the U.S.
- Revenue forecast suggests potential to reach $2 billion globally by 2030.
- Growth hinges on regulatory approvals, competitive dynamics, and pipeline expansion.
FAQs
Q1: Will Tislelizumab displace established PD-1 inhibitors?
A1: Likely not immediately. Competition remains intense, but Tislelizumab’s unique binding characteristics could provide niche advantages.
Q2: How will pricing reforms in China impact revenue?
A2: Price caps negotiated with government agencies will likely reduce per-treatment revenue but increase volume.
Q3: Which indications are most promising for growth?
A3: Lung cancer and Hodgkin’s lymphoma remain primary, with potential in solid tumors through clinical trials.
Q4: When could Tislelizumab generate significant revenue outside China?
A4: Pending regulatory approvals, especially in the U.S. and Europe, potential exists from 2025 onward.
Q5: How do biosimilars affect long-term projections?
A5: Introduction of biosimilars around 2028 could dilute pricing and reduce revenues, especially in mature markets.
References
[1] Fortune Business Insights. (2023). Oncology Immunotherapy Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com
[2] IQVIA. (2022). Global Oncology Market Report.
[3] BeiGene. (2022). Tislelizumab Regulatory Filings and Clinical Trial Data.
Note: Data estimates are based on available market reports and industry forecasts as of early 2023. Actual future performance will vary with regulatory, clinical, and commercial developments.
